340 related articles for article (PubMed ID: 24131304)
1. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge.
Scheerens H; Arron JR; Zheng Y; Putnam WS; Erickson RW; Choy DF; Harris JM; Lee J; Jarjour NN; Matthews JG
Clin Exp Allergy; 2014 Jan; 44(1):38-46. PubMed ID: 24131304
[TBL] [Abstract][Full Text] [Related]
2. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER).
Austin CD; Gonzalez Edick M; Ferrando RE; Solon M; Baca M; Mesh K; Bradding P; Gauvreau GM; Sumino K; FitzGerald JM; Israel E; Bjermer L; Bourdin A; Arron JR; Choy DF; Olsson JK; Abreu F; Howard M; Wong K; Cai F; Peng K; Putnam WS; Holweg CTJ; Matthews JG; Kraft M; Woodruff PG;
Clin Exp Allergy; 2020 Dec; 50(12):1342-1351. PubMed ID: 32909660
[TBL] [Abstract][Full Text] [Related]
3. Lebrikizumab treatment in adults with asthma.
Corren J; Lemanske RF; Hanania NA; Korenblat PE; Parsey MV; Arron JR; Harris JM; Scheerens H; Wu LC; Su Z; Mosesova S; Eisner MD; Bohen SP; Matthews JG
N Engl J Med; 2011 Sep; 365(12):1088-98. PubMed ID: 21812663
[TBL] [Abstract][Full Text] [Related]
4. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids.
Noonan M; Korenblat P; Mosesova S; Scheerens H; Arron JR; Zheng Y; Putnam WS; Parsey MV; Bohen SP; Matthews JG
J Allergy Clin Immunol; 2013 Sep; 132(3):567-574.e12. PubMed ID: 23726041
[TBL] [Abstract][Full Text] [Related]
5. OX40L blockade and allergen-induced airway responses in subjects with mild asthma.
Gauvreau GM; Boulet LP; Cockcroft DW; FitzGerald JM; Mayers I; Carlsten C; Laviolette M; Killian KJ; Davis BE; Larché M; Kipling C; Dua B; Mosesova S; Putnam W; Zheng Y; Scheerens H; McClintock D; Matthews JG; O'Byrne PM
Clin Exp Allergy; 2014 Jan; 44(1):29-37. PubMed ID: 24224471
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids.
Korenblat P; Kerwin E; Leshchenko I; Yen K; Holweg CTJ; Anzures-Cabrera J; Martin C; Putnam WS; Governale L; Olsson J; Matthews JG
Respir Med; 2018 Jan; 134():143-149. PubMed ID: 29413502
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials.
Hanania NA; Korenblat P; Chapman KR; Bateman ED; Kopecky P; Paggiaro P; Yokoyama A; Olsson J; Gray S; Holweg CT; Eisner M; Asare C; Fischer SK; Peng K; Putnam WS; Matthews JG
Lancet Respir Med; 2016 Oct; 4(10):781-796. PubMed ID: 27616196
[TBL] [Abstract][Full Text] [Related]
8. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: a randomized, double-blind, placebo-controlled clinical cross-over-trial.
Beeh KM; Beier J; Meyer M; Buhl R; Zahlten R; Wolff G
Pulm Pharmacol Ther; 2006; 19(4):233-41. PubMed ID: 16140027
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of randomized controlled trials for the efficacy and safety of anti-interleukin-13 therapy with lebrikizumab in patients with uncontrolled asthma.
Liu Y; Zhang S; Chen R; Wei J; Guan G; Zhou M; Dong N; Cao Y
Allergy Asthma Proc; 2018 Sep; 39(5):332-337. PubMed ID: 30153886
[TBL] [Abstract][Full Text] [Related]
10. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
Hanania NA; Noonan M; Corren J; Korenblat P; Zheng Y; Fischer SK; Cheu M; Putnam WS; Murray E; Scheerens H; Holweg CT; Maciuca R; Gray S; Doyle R; McClintock D; Olsson J; Matthews JG; Yen K
Thorax; 2015 Aug; 70(8):748-56. PubMed ID: 26001563
[TBL] [Abstract][Full Text] [Related]
11. The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma.
Leaker BR; Barnes PJ; O'Connor BJ; Ali FY; Tam P; Neville J; Mackenzie LF; MacRury T
Clin Exp Allergy; 2014 Sep; 44(9):1146-53. PubMed ID: 25040039
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab in persistent asthma with elevated eosinophil levels.
Wenzel S; Ford L; Pearlman D; Spector S; Sher L; Skobieranda F; Wang L; Kirkesseli S; Rocklin R; Bock B; Hamilton J; Ming JE; Radin A; Stahl N; Yancopoulos GD; Graham N; Pirozzi G
N Engl J Med; 2013 Jun; 368(26):2455-66. PubMed ID: 23688323
[TBL] [Abstract][Full Text] [Related]
13. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.
Diamant Z; Sidharta PN; Singh D; O'Connor BJ; Zuiker R; Leaker BR; Silkey M; Dingemanse J
Clin Exp Allergy; 2014 Aug; 44(8):1044-52. PubMed ID: 24964348
[TBL] [Abstract][Full Text] [Related]
14. Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study.
Siddall H; Quint D; Pandya H; Powley W; Shabbir S; Hohlfeld JM; Singh D; Lee L
PLoS One; 2020; 15(11):e0240964. PubMed ID: 33166307
[TBL] [Abstract][Full Text] [Related]
15. Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population.
Corren J; Szefler SJ; Sher E; Korenblat P; Soong W; Hanania NA; Berman G; Brusselle G; Zitnik R; Natalie CR; Sun L; Siu K; Wu WS; Lio P; Armstrong AW
J Allergy Clin Immunol Pract; 2024 May; 12(5):1215-1224.e3. PubMed ID: 38360213
[TBL] [Abstract][Full Text] [Related]
16. Lebrikizumab in the personalized management of asthma.
Thomson NC; Patel M; Smith AD
Biologics; 2012; 6():329-35. PubMed ID: 23055690
[TBL] [Abstract][Full Text] [Related]
17. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.
Wenzel S; Wilbraham D; Fuller R; Getz EB; Longphre M
Lancet; 2007 Oct; 370(9596):1422-31. PubMed ID: 17950857
[TBL] [Abstract][Full Text] [Related]
18. The late asthmatic response is associated with baseline allergen-specific proliferative responsiveness of peripheral T lymphocytes in vitro and serum interleukin-5.
van der Veen MJ; Van Neerven RJ; De Jong EC; Aalberse RC; Jansen HM; van der Zee JS
Clin Exp Allergy; 1999 Feb; 29(2):217-27. PubMed ID: 10051726
[TBL] [Abstract][Full Text] [Related]
19. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.
Krug N; Hohlfeld JM; Kirsten AM; Kornmann O; Beeh KM; Kappeler D; Korn S; Ignatenko S; Timmer W; Rogon C; Zeitvogel J; Zhang N; Bille J; Homburg U; Turowska A; Bachert C; Werfel T; Buhl R; Renz J; Garn H; Renz H
N Engl J Med; 2015 May; 372(21):1987-95. PubMed ID: 25981191
[TBL] [Abstract][Full Text] [Related]
20. Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.
Zhu R; Zheng Y; Dirks NL; Vadhavkar S; Jin JY; Peng K; Holweg CTJ; Olsson J; Matthews JG; Putnam WS
Pulm Pharmacol Ther; 2017 Oct; 46():88-98. PubMed ID: 28843617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
